SP
Spimaco Stock: price and insider trades · Saudi Arabia
Spimaco: what insiders have been doing
Insider filings for Spimaco are scarce in the Tadawul (CMA) feed, the latest one published on 24 November 2024. This page will fill in as new trades are disclosed. This summary is built from Tadawul (CMA) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Spimaco Buy (bullish), based on 4 analysts. Average price target: SAR 35.42.
Fundamental score
Ranked 9,232 of 26,897 companies
59.4
score / 100
Value58
Quality61
FCF yld5.0%
Earn yld5.3%
EV/EBITDA12.3x
ROE13%
Gross mgn49%
Net mgn11%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SAR 29.20
Analyst consensus
4 analystsBuy
SAR 30.59Target SAR 35.42(+21%)SAR 38.00
Income statement
RevenueSAR 1.7B
Gross profitSAR 832.6M49% margin
EBITDASAR 400.9M23% margin
Net incomeSAR 184.4M12.3% margin
Valuation
PER (trailing)16.3x
PER (forward)12.7x
P/Book2.1x
Beta0.39
Balance sheet & cash
Market capSAR 3.5B
Total debtSAR 1.4B
Free Cash FlowSAR 172.8M
Debt / Equity79%
Profitability & ownership
ROE12.7%
ROA3.9%
% insiders10.5%
% institutions4.4%
Last declaration on 24 November 2024
Declarations4 total
- ●Executives0Tadawul
- ●Executives0Tadawul
- ●Executives0Tadawul
- ●Executives0Tadawul
4 of 4 declarations
About Spimaco
Spimaco is a company specializing in the manufacturing of pharmaceutical products and healthcare solutions. It is listed on the XSAU market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations